PTC Therapeutics is focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. The lead asset, sepiapterin, targets adult and paediatric patients with phenylketonuria and is in Phase III development. PTC Therapeutics listed on NASDAQ in 2013.


Stuart W. Peltz

Sub segment



New Jersey, USA

Related companies

Leave a Comment

Your email address will not be published. Required fields are marked *